SCHEDULE: Vanguard Discloses 7.47% Stake in Boston Scientific

Vanguard Capital Management has reported a beneficial ownership of 7.47% in Boston Scientific Corp. common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates, now beneficially owns 111,127,205 shares of Boston Scientific Corp. common stock.
• This holding represents 7.47% of the total class of securities.
• The filing indicates sole voting power for 14,715,637 shares and sole dispositive power for 111,127,205 shares.
• The reporting date for this ownership stake is March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by a major investment firm and does not contain operational or financial performance updates from the company itself.

Positives

• Vanguard's significant stake suggests confidence in Boston Scientific's long-term prospects.
• The filing confirms Vanguard's role as a substantial institutional investor.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance from Boston Scientific Corp.

Industry Context

StockSavvy.ai notes that Vanguard's increased or maintained stake in Boston Scientific, a major player in the medical device industry, is a common indicator of institutional confidence. This sector is characterized by innovation, regulatory scrutiny, and consolidation, making significant investor positions noteworthy.

Stakeholder Impact

• Shareholders: The filing confirms Vanguard as a significant institutional shareholder, which can be viewed positively for stock stability and liquidity.
• Management: The presence of a large, stable institutional investor like Vanguard can influence corporate governance and strategic decisions.

Key Dates

Keywords

Boston Scientific, Vanguard Capital Management, Schedule 13G, SEC Filing, Beneficial Ownership, Institutional Investor, Common Stock, Medical Devices